As ABI Unveils New Mass Spec for Metabolomics Market, Can It Convince Big Pharma to Buy It? | GenomeWeb

SAN FRANCISCO — Applied Biosystems last week launched the API 5000 LC/MS/MS System, a triple-quadrupole mass spectrometry platform co-developed with MDS Sciex that will serve as ABI’s flagship product for the emerging metabolomics market.

The company rolled out the $450,000 instrument and software platform as Cathy Burzik, ABI’s president, presented at the JPMorgan Healthcare conference last week.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.